Novacyt S.A.
("Novacyt", the "Company" or the
"Group")
Launch of new animal multiplex assays at
London Vet Show
Rapid, accurate detection of six
gastrointestinal disease-causing pathogens in cats and
dogs
Paris, France, Eastleigh and
Manchester, UK - 14 November 2024 - Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international molecular diagnostics
company with a broad portfolio of integrated technologies and
services,
announces that it is launching two new assays for gastrointestinal
disease in dogs and cats at the London Vet Show, held from 14-15
November 2024.
The
genesig®PLEX kits for Canine and Feline Gastrointestinal (GI)
Diseases are multiplexed qPCR assays that detect six
disease-causing pathogens in the digestive system of cats and dogs
in a two-tube assay, delivering a streamlined and efficient testing
solution for centralised veterinary laboratories. Each target has
been carefully selected to detect a key pathogen that can cause
potentially serious or life-threatening GI illnesses in cats and
dogs.
Testing
for six pathogens using one sample will reduce hands-on time for
laboratory technicians as well as the use of consumables. The kits
provide results in less than three hours, enabling quicker, more
comprehensive results to the veterinarian and ensuring faster
treatment for the family pet.
If you
are attending the London Vet Show and would like further
information on the new genesig®PLEX kits for Canine and Feline
Gastrointestinal (GI) Diseases, or Novacyt's wider portfolio of
veterinary assays, the Novacyt team can be found at Booth No
A49.
Lyn Rees, CEO of Novacyt,
said: "Following consultation with our
customers and further market research, we saw clear demand in the
veterinary industry for multiplex assays that target several
companion animal pathogens using a single sample. With the launch
of our two new genesig®PLEX kits for cats and dogs, we are making
testing for these gastrointestinal pathogens more cost-effective,
faster and less hands-on for laboratories, and enabling quicker
results for veterinarians.
"Adding to the 200+ veterinary assays
in Primer Design's existing portfolio, these tests demonstrate our
continued commitment to identifying emerging diagnostic needs and
providing best-in-class solutions for our
customers."
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn Rees, Chief Executive
Officer
|
Via Walbrook
PR
|
|
Steve Gibson, Chief Financial
Officer
|
|
|
SP
Angel Corporate Finance LLP (Nominated Adviser and
Broker)
|
+44 (0)20
3470 0470
|
|
Matthew Johnson / Charlie Bouverat
(Corporate Finance)
Vadim Alexandre / Rob Rees
(Corporate Broking)
|
|
|
|
|
|
Deutsche Numis (Joint
Broker)
|
+44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick
Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR (Financial PR & IR)
Paul McManus / Lianne
Applegarth
Phillip Marriage / Alice
Woodings
|
+44 (0)20
7933 8780 or novacyt@walbrookpr.com
+44
(0)7980 541 893 / +44 (0)7584 391 303
+44
(0)7867 984 082 / +44 (0)7407 804 654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an international
molecular diagnostics company providing a broad portfolio of
integrated technologies and services, primarily focused on the
delivery of genomic medicine. The
Company develops, manufactures, and
commercialises a range of molecular assays
and instrumentation to deliver workflows and services that enable
seamless end-to-end solutions from sample to result across multiple
sectors including human health, animal health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical
in vitro diagnostic
products, workflows and services focused on three therapeutic
areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex winter
respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size
selection DNA sample preparation platforms and rapid
PCR machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
·
genesig q16 and q32 real-time quantitative PCR
(qPCR) instruments
|
|
Research Use Only
|
Range of services for the life
sciences industry:
·
Design, manufacture, and supply of
high-performance qPCR assays and workflows for use in human health,
agriculture, veterinary and environmental, to support global health
organisations and the research industry
·
Pharmaceutical research services: whole genome
sequencing (WGS) / whole exome sequencing (WES)
|
Novacyt is headquartered in
Vélizy-Villacoublay in France with offices in the UK (in Eastleigh
and Manchester), Singapore, the US and Canada and has a commercial
presence in over 65 countries. The Company is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock
Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com
About the London Vet Show
The London Vet Show is Europe's
largest veterinary conference and exhibition. Run with education
partners the Royal Veterinary College and British Veterinary
Association, the London Vet Show brings together thousands of
veterinary professionals, innovators and industry
giants, with over 400 exhibitors and 200
speakers.